Avadel Pharmaceuticals Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avadel Pharmaceuticals stock.
View analyst ratings for Avadel Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Avadel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avadel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Avadel Pharmaceuticals.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its quarterly earnings data on Sunday, May, 9th. The company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.09.
View Avadel Pharmaceuticals' earnings history.

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVDL stock has decreased by 1.8% and is now trading at $7.85.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued 12-month target prices for Avadel Pharmaceuticals' shares. Their forecasts range from $17.00 to $22.00. On average, they expect Avadel Pharmaceuticals' share price to reach $18.75 in the next year. This suggests a possible upside of 138.9% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Avadel Pharmaceuticals include Protagonist Therapeutics (PTGX), Seres Therapeutics (MCRB), Harmony Biosciences (HRMY), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Cerevel Therapeutics (CERE), Arcus Biosciences (RCUS), Aurinia Pharmaceuticals (AUPH), Constellation Pharmaceuticals (CNST), Heron Therapeutics (HRTX), Indivior (INVVY), uniQure (QURE) and ADC Therapeutics (ADCT).
View all of AVDL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (9.82%), Vivo Capital LLC (5.02%), Brandes Investment Partners LP (5.02%), Polar Capital Holdings Plc (4.78%), Cowen AND Company LLC (4.27%) and Acuta Capital Partners LLC (1.87%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Millennium Management LLC, Asymmetry Capital Management L.P., Polar Capital Holdings Plc, JPMorgan Chase & Co., Pura Vida Investments LLC, Renaissance Technologies LLC, and Iridian Asset Management LLC CT.
View insider buying and selling activity for Avadel Pharmaceuticals or view top insider-selling stocks.

AVDL stock was acquired by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, Frazier Management LLC, Acuta Capital Partners LLC, RTW Investments LP, Knott David M, Samsara BioCapital LLC, CIBC Private Wealth Group LLC, and Investors Asset Management of Georgia Inc. GA ADV. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, and Thomas S Mchugh.
View insider buying and selling activity for Avadel Pharmaceuticals or or view top insider-buying stocks.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVDL stock can currently be purchased for approximately $7.85.

Avadel Pharmaceuticals has a market capitalization of $459.13 million and generates $22.33 million in revenue each year. The company earns $7.03 million in net income (profit) each year or ($0.75) on an earnings per share basis.

Avadel Pharmaceuticals employs 32 workers across the globe.

The official website for Avadel Pharmaceuticals is www.avadel.com.

Avadel Pharmaceuticals is headquartered at 10 EARLSFORT TERRACE, DUBLIN L2, D02.

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at 011-1-485-1200 or via email at [email protected]